Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Daniel Victor Ortigoza: Apixaban Shows Lower Bleeding Risk than Rivaroxaban in Acute VTE
Daniel Victor Ortigoza/LinkedIn
Mar 17, 2026, 14:55

Daniel Victor Ortigoza: Apixaban Shows Lower Bleeding Risk than Rivaroxaban in Acute VTE

Daniel Victor Ortigoza, 2nd Vice President of the Cardio-Oncology Committee at the Argentine Federation of Cardiology and President of the Arrhythmias and Electrophysiology Committee of the Argentine Federation of Cardiology, shared a post on LinkedIn about a recent article by Lana A. Castellucci et al, published in The New England Journal of Medicine։

”Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism

Patients with DVT or PE were randomly assigned in a 1:1 ratio to rivaroxaban 15 mg twice daily for 21 days, apixaban 20 mg/day or apixaban 10 mg twice daily for 7 days, followed by apixaban 5 mg twice daily, both groups for 3 months.

The primary outcome (PO) was clinically relevant bleeding (CRB), a composite of clinically relevant non-major bleeding (CRNMB) or clinically relevant non-major bleeding according to the ISTH, and major bleeding (MB). The secondary outcomes (SO) were the individual components of the primary PE: recurrent DVT/PE.

CRB was observed in 3.3% with Apixaban versus 7.1% with Rivaroxaban (Relative Risk: 0.46; 95% CI, 0.33 to 0.65; P<0.001). MB 0.4% versus 2.4%; Relative Risk: 0.16; 95% CI, 0.06 to 0.40.

The percentage of DVT/PE recurrence was similar in the two treatment groups at 3 months

These data cannot be extrapolated to atrial fibrillation; the COBBRA-AF study on atrial fibrillation is currently underway.”

Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism

Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger

Read the Full Article on The New England Journal of Medicine

Daniel Victor Ortigoza: Apixaban Shows Lower Bleeding Risk than Rivaroxaban in Acute VTE

Stay updated on all scientific advances with Hemostasis Today.

Abbey Willcox Acute Venous Thromboembolism Alejandro Lazo-Langner Apixaban Benoit Côté Clive Kearon Deepa Suryanarayan Erik Yeo Erin Thomas Etimbuk Umana Fionnuala Ní Áinle Genevieve Le Templier Gregoire Le Gal Health Helen J. Crowther Hematology Hemostasis News Hemostasis Today Huyen A. Tran James Douketis Jean-Philippe Galanaud Kerstin de Wit Lana A. Castellucci Lisa Baumann Kreuziger Marc Blondon Marc Rodger Medicine Michael J. Kovacs Peter Greenstreet Ritam Prasad Sam Schulman Stefano Barco Sudeep Shivakumar Susan Kahn Susan Solymoss Tim Ramsay Tobias Tritschler Tony Wan Vivien M. Chen
NewsFeed